<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02895373</url>
  </required_header>
  <id_info>
    <org_study_id>ECMO_PGE1_2.1</org_study_id>
    <nct_id>NCT02895373</nct_id>
  </id_info>
  <brief_title>PGE1 as Additive Anticoagulant in ECMO-Therapy</brief_title>
  <acronym>ECMO_PGE1</acronym>
  <official_title>A Prospective Randomized, Double Blind Study on Safety and Efficacy of Alprostadil as Additional Anticoagulant in Patients With Veno- Venous Extracorporeal Membrane Oxygenation (ECMO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Staudinger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bleeding complications and thromboembolic complications are frequent during extracorporeal
      membrane oxygenation (ECMO). Retrospective data suggest that platelet inhibition using
      prostaglandins, in this case PGE1, may reduce thromboembolic complications without increasing
      the bleeding risk. This randomized, double-blind trial aims to investigate the effects of
      PGE1 on bleeding risk, thromboembolic complications and the function of the ECMO.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostaglandins may inhibit platelet activation via the P2Y1 ADP receptor. Platelets may
      contribute to thromboembolic complications and coagulation activation during ECMO therapy.
      Retrospective data suggest that treatment with PGE1 may serve beneficial by reducing the
      amount of heparin needed for inhibition of coagulation activation, and by reducing the
      thromboembolic risk without increasing the risk of bleeding.

      Inhibition of platelets via PGE1 (Alprostadil) may be interesting in this setting, because,
      in contrast to other platelet inhibitors, it has a very short half-life and platelets remain
      susceptible for activation by more potent agonists (i.e. thrombin, ADP). Thus, although
      reducing the contribution of platelets to coagulation activation, it may not affect safety of
      participating subjects.

      This randomized, double-blind, placebo controlled trial will investigate whether treatment of
      patients with ECMO therapy proves beneficial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding rate (quantified by the number of packed red blood cells transfused in relation to the duration of ECMO therapy)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The bleeding rate will be quantified by the number of packed red blood cells in relation to the duration of ECMO therapy. This duration may vary and cannot be predicted. Thus, we will calculate the required number of packed red blood cells i.e. per week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of bleeding incidences and severity of bleeding (bleeding grades)</measure>
    <time_frame>up to six months</time_frame>
    <description>type 0: no bleeding type1: bleeding that is not actionable type 2: any overt actionable sign of hemorrhage type3: a) overt bleeding plut hb drop of 3-5g/dl b) &gt;5g/dl, cardiac tamponade, requiring surgical intervention, bleeding requiring vasoactive agents c)intracranial bleeding, type 5: fatal bleeding
number and severity of bleeding relative to the duration of ECMO therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clotting Events</measure>
    <time_frame>up to six months</time_frame>
    <description>clinically noticeable thromboembolic events
cannulized veins (Duplex 24h after canula removal)
need of Membrane- changes,, macroscopic thrombus, discoloration
Global clotting tests (prothrombin time, activated partial thromboplastin time, Fibrinogen, D-Dimer)
number of Clotting events in relation to the duration of ECMO therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function of the membrane oxygenator</measure>
    <time_frame>up to six months</time_frame>
    <description>The function of the membrane oxygenator will be assessed on a daily basis as part of clinical routine.This includes the capacity of oxygen transfer and carbon-dioxide (CO2) transfer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of changes of the membrane oxygenator relative to the duration of ECMO therapy</measure>
    <time_frame>up to six months</time_frame>
    <description>Membrane oxygenators need to be changed due to loss of function (cause by clotting etc.).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation specific biomarkers (i.e. C-reactive protein, blood counts, reticulated platelets, etc.)</measure>
    <time_frame>Time points: Immediately prior to initiation of ECMO, 24, 48 and 72h after initiation of ECMO, then twice a week until end of ECMO therapy, up to 12 months</time_frame>
    <description>daily routine measurements and frozen plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Coagulation assays</measure>
    <time_frame>Time points: Immediately prior to initiation of ECMO, 24, 48 and 72h after initiation of ECMO, then twice a week until end of ECMO therapy, up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboelastometry</measure>
    <time_frame>Time points: Immediately prior to initiation of ECMO, 24, 48 and 72h after initiation of ECMO, then twice a week until end of ECMO therapy, up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet function analyzer-100</measure>
    <time_frame>Time points: Immediately prior to initiation of ECMO, 24, 48 and 72h after initiation of ECMO, then twice a week until end of ECMO therapy, up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen levels</measure>
    <time_frame>Time points: Immediately prior to initiation of ECMO, 24, 48 and 72h after initiation of ECMO, then twice a week until end of ECMO therapy, up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>whole blood aggregometry</measure>
    <time_frame>Time points: Immediately prior to initiation of ECMO, 24, 48 and 72h after initiation of ECMO, then twice a week until end of ECMO therapy, up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-Dimer levels</measure>
    <time_frame>Time points: Immediately prior to initiation of ECMO, 24, 48 and 72h after initiation of ECMO, then twice a week until end of ECMO therapy, up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catecholamines</measure>
    <time_frame>Time points: Immediately prior to initiation of ECMO, 24, 48 and 72h after initiation of ECMO, then twice a week until end of ECMO therapy, up to 12 months</time_frame>
    <description>need for and dose of catecholamines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac output</measure>
    <time_frame>Time points: Immediately prior to initiation of ECMO, 24, 48 and 72h after initiation of ECMO, then twice a week until end of ECMO therapy, up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>Time points: Immediately prior to initiation of ECMO, 24, 48 and 72h after initiation of ECMO, then twice a week until end of ECMO therapy, up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>Day 28/90, ICU mortality assessed at the discharge from the Intensive Care unit, this will be up to 12 months after inclusion into the study</time_frame>
    <description>by chart review or telephone call</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of platelet transfusions, fresh frozen plamsa, coagulation interventions etc.</measure>
    <time_frame>up to six months</time_frame>
    <description>by chart review, number relative to the duration of ECMO therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of platelet transfusions</measure>
    <time_frame>up to six months</time_frame>
    <description>by chart review, number relative to the duration of ECMO therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of coagulation interventions</measure>
    <time_frame>up to six months</time_frame>
    <description>by chart review, number relative to the duration of ECMO therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <condition>Extracorporeal Membrane Oxygenation</condition>
  <arm_group>
    <arm_group_label>Alprostadil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>heparin (dose adjusted to aptt 50-60s) + Alprostadil (=PGE1) 5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>heparin (dose adjusted to aptt 50-60s) + 0.9% sodium chloride infusion, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprostadil</intervention_name>
    <description>5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy</description>
    <arm_group_label>Alprostadil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% sodium chloride solution</intervention_name>
    <description>continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  minimum age 18 years

               -  Veno-Venous- ECMO

               -  Minimum of 24h planned ECMO- therapy

        Exclusion Criteria:

          -  â€¢ Long- term therapy with other antiplatelet drugs including Acetyl Salicylic Acid

               -  known Heparin induced thrombocytopenia

               -  Bleeding diathesis = contraindication for heparin (e.g. GI-bleeding,
                  Intracerebral bleeding)

               -  Platelets &lt; 50 G/L

               -  Thromboplastin time &lt; 50%

               -  Pregnancy

               -  Patient &lt; 18 years

               -  prothrombin time &lt;50%

        Drop out criteria:

          -  Major bleeding (from Type 3 bleeding; see &quot;primary objective&quot;)

          -  Occurrence of HIT (4 T- Score: Number of platelets, development over time,
             manifestation of thrombosis, other reasons for thrombocytopenia [10])

          -  Plt &lt; 50 G/l
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Staudinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Staudinger, MD</last_name>
    <phone>+43 1 40400</phone>
    <phone_ext>44920</phone_ext>
    <email>thomas.staudinger@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katharina Riss, MD</last_name>
    <phone>+43 1 40400</phone>
    <phone_ext>44920</phone_ext>
    <email>katharina.riss@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Medicine I, Intensive Care Unit</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Staudinger, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>44920</phone_ext>
      <email>thomas.staudinger@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Katharina Riss, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>44920</phone_ext>
      <email>katharina.riss@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Schoergenhofer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Staudinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katharina Riss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernd Jilma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Schellongowski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andja Bojic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Thomas Staudinger</investigator_full_name>
    <investigator_title>Ao.Univ.Prof. Dr. med</investigator_title>
  </responsible_party>
  <keyword>platelet inhibition</keyword>
  <keyword>alprostadil</keyword>
  <keyword>extracorporeal membrane oxygenation</keyword>
  <keyword>bleeding</keyword>
  <keyword>thromboembolic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be published in a peer-reviewed journal, individual data will not be made publicly available except by a direct request to the PI (in an anonymized fashion)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

